Drug Trial Radar · NCT07863193
Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
800
Planned (sponsor's estimate)
Start
Oct 21, 2026
Primary completion
Aug 2027
Study completion Apr 2028
Sponsor
- Lead sponsor
- Sagimet Biosciences Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of denifanstat compared with matching placebo in participants with moderate to severe acne vulgaris who are ≥12 years of age. After the 12-week treatment phase, a subset of approximately 530 participants will have the option to consent to an open-label extension phase for an additional 40 weeks of treatment.
Conditions
- Acne Vulgaris
Interventions
DenifanstatDrug
Oral, once daily
PlaceboOther
Oral, once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants achieving EGSS success, defined as a score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease from their baseline scoreTime frame: Week 12
- Absolute change from baseline in inflammatory lesion count (ILC)Time frame: Week 12
- Absolute change from baseline in non-inflammatory lesion count (ILC)Time frame: Week 12
Locations
35 sites in 1 country. Site status is shown where the registry gives one.
Sagimet Investigative Site
Bryant, Arkansas · Recruiting
Sagimet Investigative Site
Beverly Hills, California · Recruiting
Sagimet Investigative Site
Fremont, California · Recruiting
Sagimet Investigative Site
San Diego, California · Recruiting
Sagimet Investigative Site
Santa Ana, California · Recruiting
Sagimet Investigative Site
Doral, Florida · Recruiting
Sagimet Investigative Site
Fort Lauderdale, Florida · Recruiting
Sagimet Investigative Site
Miami, Florida · Recruiting
Sagimet Investigative Site
Miami, Florida · Recruiting
Sagimet Investigative Site
Miami, Florida · Recruiting
Sagimet Investigative Site
Miami, Florida · Recruiting
Sagimet Investigative Site
Miramar, Florida · Recruiting
Sagimet Investigative Site
Sweetwater, Florida · Recruiting
Sagimet Investigative Site
Lincolnshire, Illinois · Recruiting
Sagimet Investigative Site
Indianapolis, Indiana · Recruiting
Sagimet Investigative Site
New Albany, Indiana · Recruiting
Sagimet Investigative Site
Plainfield, Indiana · Recruiting
Sagimet Investigative Site
Brighton, Massachusetts · Recruiting
Sagimet Investigative Site
Ann Arbor, Michigan · Recruiting
Sagimet Investigative Site
Clinton Township, Michigan · Recruiting
Sagimet Investigative Site
Saint Joseph, Missouri · Recruiting
Sagimet Investigative Site
Omaha, Nebraska · Recruiting
Sagimet Investigative Site
Portsmouth, New Hampshire · Recruiting
Sagimet Investigative Site
Robbinsville, New Jersey · Recruiting
Sagimet Investigative Site
Wilmington, North Carolina · Recruiting
Sagimet Investigative Site
Columbus, Ohio · Recruiting
Sagimet Investigative Site
East Greenwich, Rhode Island · Recruiting
Sagimet Investigative Site
Greenville, South Carolina · Recruiting
Sagimet Investigative Site
Murfreesboro, Tennessee · Recruiting
Sagimet Investigative Site
Nashville, Tennessee · Recruiting
Sagimet Investigative Site
College Station, Texas · Recruiting
Sagimet Investigative Site
El Paso, Texas · Recruiting
Sagimet Investigative Site
Houston, Texas · Recruiting
Sagimet Investigative Site
San Antonio, Texas · Recruiting
Sagimet Investigative Site
Spokane, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.